Novartis AG (NVSEF)
OTCMKTS
· Delayed Price · Currency is USD
109.97
+2.77 (2.58%)
Mar 31, 2025, 9:55 AM EST
Novartis AG Employees
Novartis AG had 75,883 employees as of December 31, 2024. The number of employees decreased by 174 or -0.23% compared to the previous year.
Employees
75,883
Change (1Y)
-174
Growth (1Y)
-0.23%
Revenue / Employee
$681,602
Profits / Employee
$157,361
Market Cap
210.03B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75,883 | -174 | -0.23% |
| Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
| Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
| Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
| Dec 31, 2020 | 105,794 | 1,880 | 1.81% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 2,931 |
| Elite Pharmaceuticals | 64 |
| Glass House Brands | 413 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 9 |
| Silence Therapeutics | 116 |
| American Oncology Network | 1,525 |
Novartis AG News
- 3 days ago - FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool - Benzinga
- 3 days ago - FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer - GlobeNewsWire
- 6 days ago - Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis - GlobeNewsWire
- 10 days ago - FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease - Benzinga
- 10 days ago - Novartis receives third FDA approval for oral Fabhalta treatment for kidney disease C3G - Seeking Alpha
- 10 days ago - Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G) - PRNewsWire
- 11 days ago - Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) - GlobeNewsWire
- 11 days ago - Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders - Benzinga